Is TGTX stock a Buy, Sell, or Hold?

Based on our analysis, TGTX is currently a HOLD with moderate confidence. 📊 HOLD: TGTX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.

What is the fair value of TGTX stock?

Our analysis estimates the fair value range for TGTX to be between $49.99 and $56.59. The current price is $47.94.

What is the analyst price target for TGTX?

The average Wall Street analyst price target for TGTX is $69.71. This implies a potential upside of 45.4% from current levels.

TGTX Stock Analysis: Buy, Sell, or Hold?

TGTX - TG Therapeutics, Inc.

PHARMACEUTICAL PREPARATIONS

$47.94

-1.56 (-3.15%) ▼

5d: -3.25%

30d: -15.02%

90d: +12.4%

HOLD

MODERATE Confidence

Protect Your TGTX Gains

Analysis Updated: Aug 13, 2026 12:00 AM ET

Earnings: Aug 03, 2026 0d

Smart Money Accumulation

Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →

Signal fired Aug 7, 2026 at $49.76 · last confirmed Aug 13, 2026

Strength: 7.3/10

Get Alerted When TGTX Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.

100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

💡

Bottom Line:
📊 HOLD: TGTX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.

See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

Adjust Growth Assumption: 25.0%

0% (Stagnation) 50% (Hyper Growth)

EST. PRICE IN 2031

$91.23

Based on 14.5% avg growth

INTRINSIC VALUE TODAY

$56.65

15.4% Margin of Safety

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.8x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: TGTX is currently trading at $47.94, which is considered oversold relative to its 30-day fair value range of $49.99 to $56.59. The stock's valuation (Forward PE: 16.2) is in line with its historical norms (15.8). At these levels, the market is pricing in 0.9% annual earnings growth.

Technical Outlook: Technically, TGTX is in a strong uptrend. Immediate support is located at $45.37, while resistance sits at $53.46. Short-term momentum is weak, with the stock down 3.2% recently.

Market Sentiment: The stock scores a mixed 54/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $69.71 (+45.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.

Quick Decision Summary

Current Position OVERSOLD

Historical Trading Range $49.99 - $56.59

Company Quality Score 60/100 (HOLD)

Volume Confirmation HIGH

Confidence Score 78.1%

Protect Your Profits

Holding TGTX? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

All Signals

BULLISH: Price oversold vs 30-day range
NEUTRAL: Mixed technical signals (54/100)
BULLISH: High volume confirmation
BEARISH: Downward momentum (-3.2%)
BULLISH: Trading 45.4% below Wall St target ($69.71)
BULLISH: Expecting earnings turnaround to 0.9% growth with 70.3% revenue growth
NEUTRAL: Bottoming setup forming (54/100) — watch for confirmation

Trading Range Analysis

30-Day Trading Range $49.99 - $56.59

Current vs Trading Range OVERSOLD

Support & Resistance Levels

Support Level $45.37

Resistance Level $53.46

Current Trend Strong Uptrend

Technical data as of Aug 13, 2026

Fundamental Context

Forward P/E (Next Year Est.) 16.17

Wall Street Target $69.71 (+45.4%)

Revenue Growth (YoY) 70.3%

Earnings Growth (YoY) -70.6%

Profit Margin 55.2%

Valuation Premium vs History +0.9% premium

PE vs Historical 16.2 vs 15.8 FAIR

Market-Implied Price Targets If current PE multiple persists

Implied Growth (YoY): +0.9% (market-implied from PE analysis)

1-Year Target $48.37 (+1%)

2-Year Target $48.81 (+2%)

3-Year Target $49.25 (+3%)

3-Yr Target (if PE normalizes) (PE: 16→16) PE COMPRESSION $48.12 (+0%)

Earnings growth offset by PE compression

3-Year Scenarios Using analyst projected EPS growth

Bull: (PE: 20.2, Growth: 212.1%) $202.44 (+322%)

Base: (SPY PE: 16.2, Growth: 212.1%) $161.80 (+238%)

Bear: (PE: 13.7, Growth: 212.1%) $137.53 (+187%)

📈 Valuation based on Current Earnings

RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (16x PE) as earnings recover.

Trailing PE: 18.20 | Current EPS (TTM): $2.72

Bull Case $59.35 (+24%)

Analyst growth 9.0%, PE expands to 20.0

Base Case $53.96 (+13%)

Market implied 9.0%, PE stable at 18.2

Bear Case $33.66 (-30%)

Severe decline -20.0%, PE contracts to 15.5

These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.

Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit

bloggers & journalists: you are free to use our charts with attribution.

Last updated: August 14, 2026 3:52 AM ET
Data refreshes hourly during market hours. Next update: 4:52 AM

🔥 Top Stocks Breaking Out Now

Ticker	Score	Recommendation	Change %

See Full Scanner Results »

Technical Signals Check

Is TGTX showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check

Insider Activity (6 Months)

Buys

Sells

Net

NEUTRAL

View Insider Activity Scanner

Unlock Insider Activity

See real-time buying/selling by company executives for TGTX.

Create Free Account

Already have an account? Log In

Top Rated Biotechnology Stocks

Top-rated stocks in Biotechnology by analyst ratings.

Stock	Analyst Consensus	Analyst Target	Tradestie Score
CYTK Cytokinetics Inc	STRONG BUY 21 analysts	$108	54 HOLD
CRSP Crispr Therapeutics AG	BUY 28 analysts	$88	39 SELL
INSM Insmed Inc	STRONG BUY 21 analysts	$198	28 SELL
CRNX Crinetics Pharmaceutical…	STRONG BUY 17 analysts	$86	48 HOLD
IMCR Immunocore Holdings Ltd	STRONG BUY 17 analysts	$64	64 BUY

CYTK Cytokinetics Inc

54 HOLD

CRSP Crispr Therapeuti…

39 SELL

INSM Insmed Inc

28 SELL

CRNX Crinetics Pharmac…

48 HOLD

IMCR Immunocore Holdin…

64 BUY

Advanced TGTX Option Strategies

Professional options setups generated by AI based on today's TGTX price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for TGTX

TGTX Technical Chart TGTX Price Prediction TGTX Earnings Date TGTX Investment Advisor TGTX Fair Price Analyzer TGTX Options Advisor TGTX Options Chain TGTX Options Analysis TGTX Competitors

Compare TGTX with Peers

TGTX vs AXSM
Which one to buy?

TGTX vs AUPH
Which one to buy?

TGTX vs IOVA
Which one to buy?

TGTX vs KPTI
Which one to buy?

TGTX vs MDGL
Which one to buy?

PTCT vs TGTX
Winner: PTCT

SRRK vs TGTX

TGTX vs IOVA

Create New Comparison View All Competitors

Tradestie